Instead of focusing on whole-genome sequencing, which they all said was still too expensive, the three pharma companies are focusing on either specific genes, a portion of the exome, or the transcriptome.
SpeeDx, a spinout of Johnson & Johnson's Australian research subsidiary, claims its multi-component nucleic acid enzymes, or MNAzymes, provide significant advantages over current enzymes for multiplex qPCR applications.
The Dutch array vendor is working closely with partners in the pharmaceutical industry and academia to optimize internally developed kinase-screening assays for use in drug discovery and as companion diagnostics.
Under the CRADA, Ortho Biotech, a unit of J&J's Centocor, will have an option to exclusively license new inventions developed jointly or independently by NCI scientists. The collaboration will focus on engineering patients' T-cells to treat melanoma and possibly other types of cancers.
CGC Genetics, Nuvera Biosciences, Veridex, ImaGenes, CapitalBio, Fisher Healthcare, Osmetech, National Institutes of Health, Clinical Data, Cogenics, UK Biotechnology and Biological Sciences Research Council